Vaddi Krishna - 04 Feb 2026 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: CEO, Director
Issuer ticker: PRLD
Reported as of: 04 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Feb 2026, 16:10:06 UTC
Prior SEC filing: 27 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Bryant D. Lim, Attorney-in-Fact

Key filing fact

Vaddi Krishna filed Form 4 for Prelude Therapeutics Inc (PRLD) on 05 Feb 2026.

Key facts

This page summarizes Vaddi Krishna's Form 4 filing for Prelude Therapeutics Inc (PRLD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2026, 16:10.

Change

Previous filing in this sequence was filed on 27 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001824633 Primary reporting owner

Vaddi Krishna

Relationship: CEO, Director
Address: C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON
Signature: /s/ Bryant D. Lim, Attorney-in-Fact
Signature date: 05 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +837,000
Change %
Price: $0.000000
Shares after: 837,000
Date: 04 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 837,000
Exercise price: $2.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.